RE: Onwards and upwards17 Jun 2021 08:45
@Treacle, it's more of a rumour unless and until formally confirmed or denied by NIH. As such it isn't price sensitive information available to the BOD, simply a rumour.
Synairgen did respond, however through Twitter. It's what I call a 'soft RNS' - informing on something outside their control and which they are unable to manage. Yes, it may be influential on pricing, but a rumour doesn't always force the company to issue a full RNS.
I did like the 'soft RNS', though! Lots of lines to read in between....